4-methoxy-2-phenoxynicotinonitrile | 339016-67-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-methoxy-2-phenoxynicotinonitrile
• 英文别名: 4-methoxy-2-phenoxypyridine-3-carbonitrile
• CAS: 339016-67-0
• 化学式: C₁₃H₁₀N₂O₂
• 分子量: 226.235
• InChiKey: AYKVTTDUUVLXPI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  55.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-methoxy-2-phenoxynicotinonitrile 在 一水合肼 作用下， 以 乙醇 为溶剂， 生成 4-phenoxy-1H-pyrazolo[4,3-c]pyridin-3-amine
  参考文献：
  名称：

  Structure-driven HtL: Design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity

  摘要：

  The design and synthesis of a new series of c-Jun N-terminal kinase inhibitors are reported. The novel series of substituted amino indazoles were designed based on a combination of hits from high-throughput screening and X-ray crystal structure information of the compounds crystallised into the JNK-1 ATP binding site. C 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.008
• 作为产物：
  描述：

  1,1-dicyano-2-methoxy-4-(N,N-dimethylamino)-1,3-butadiene 在 盐酸 、 caesium carbonate 作用下， 以 甲醇 为溶剂， 生成 4-methoxy-2-phenoxynicotinonitrile
  参考文献：
  名称：

  Structure-driven HtL: Design and synthesis of novel aminoindazole inhibitors of c-Jun N-terminal kinase activity

  摘要：

  The design and synthesis of a new series of c-Jun N-terminal kinase inhibitors are reported. The novel series of substituted amino indazoles were designed based on a combination of hits from high-throughput screening and X-ray crystal structure information of the compounds crystallised into the JNK-1 ATP binding site. C 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.05.008

文献信息

• [EN] PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS CONTENANT DE LA PIPÉRIDINE ET LEURS UTILISATIONS
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2010080864A1

  公开（公告）日：2010-07-15

  A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I) wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

  一种预防和/或治疗代谢性疾病、脑血管疾病等的方法，包括向哺乳动物施用化合物的有效量，其化学式为(I)，其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂合物或前药。以及化学式(I-1)的新化合物：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂合物或前药具有抗糖尿病作用和神经保护作用。因此，化合物(I)和化合物(I-1)在预防和/或治疗代谢性疾病如糖尿病、脑血管疾病如中风等方面是有用的。
• [EN] INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF<br/>[FR] DÉRIVÉS D'INDAZOLE/PYRZOLO[4,3-C]PYRIDINE UTILISÉS COMME INHIBITEURS DE JNK, COMPOSITIONS ET MÉTHODE S'Y RAPPORTANT ET PRODUITE INTERMÉDIAIRE
  申请人：ASTRAZENECA AB

  公开号：WO2004113303A1

  公开（公告）日：2004-12-29

  The present invention relates to new compounds of formula (I) in which:X is CR4 or N; R1 is -OR5, -NHCOR6 or -NR6R7; R2 is hydrogen, Oar1 or -NHAr1 wherein Ar1 is aryl optionally substituted with one or more of R8, -OR8, -NR8R9, -CONR8R9, -COOR8, -NR8COR9, -SR8, -SO2NR8R9, -NR8SO2 R9, halogen, cyano, or nitro; R3 is hydrogen or -NHAr2 wherein Ar2 is benzene optionally substituted with one or more of R8, -OR8, -NR8R9, halogen or nitro, wherein R2 and R3 is not simultaneously hydrogen; a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明涉及公式（I）的新化合物，其中：X为CR4或N；R1为-OR5，-NHCOR6或-NR6R7；R2为氢，Oar1或-NHAr1，其中Ar1是芳基，可选择地取代一个或多个R8，-OR8，-NR8R9，-CONR8R9，-COOR8，-NR8COR9，-SR8，-SO2NR8R9，-NR8SO2R9，卤素，氰基或硝基；R3为氢或-NHAr2，其中Ar2是苯，可选择地取代一个或多个R8，-OR8，-NR8R9，卤素或硝基，其中R2和R3不同时为氢；一种制备它们的方法和在其中使用的新中间体，含有所述治疗活性化合物的制药配方以及所述活性化合物在治疗中的使用。
• Substituent Effects of 2-Pyridones on Selective O-Arylation with Diaryliodonium Salts: Synthesis of 2-Aryloxypyridines under Transition­-Metal-Free Conditions
  作者：Dong-Liang Mo、Xiao-Hua Li、Ai-Hui Ye、Cui Liang

  DOI：10.1055/s-0036-1591884

  日期：2018.4

  An efficient transition-metal-free strategy to synthesize 2-aryloxypyridine derivatives has been developed by a selective O-arylation of 2-pyridones with diaryliodonium salts. The reaction was compatible with a series of functional groups for 2-pyridones and diaryliodonium salts such as halides, nitro, cyano, and ester groups. The substituents at the C6-position of 2-pyridones favored O-arylation products because of steric hindrance. The reaction was easily performed on a gram-scale and 6-chloro-2-pyridone was a good precursor to access various unsubstituted 2-aryloxypyridines by dehalogenation. A P2Y1 lead compound analogue could be prepared in good yield over two steps.

  开发了一种高效的过渡金属自由策略，通过选择性的氧芳基化2-吡啶酮与二芳基碘盐合成2-芳氧基吡啶衍生物。该反应与一系列功能团对2-吡啶酮和二芳基碘盐兼容，如卤素、硝基、氰基和酯基等。2-吡啶酮的C6位取代基有利于氧芳基化产物的生成，因为存在立体位阻。该反应易于在克级规模上进行，并且6-氯-2-吡啶酮是通过去卤代法获得各种未取代的2-芳氧基吡啶的良好前体。通过两步反应可以以较高产率制备P2Y1前体类似物。
• PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF
  申请人：Rodriguez Martha E.

  公开号：US20110275608A1

  公开（公告）日：2011-11-10

  A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

  一种预防和/或治疗代谢性疾病、脑血管疾病等的方法，包括向哺乳动物投与公式(I)化合物的有效量：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂化物或前药。公式(I-1)的新化合物：其中所有符号的含义与规范中定义的相同；其盐、N-氧化物、溶剂化物或前药具有抗糖尿病和神经保护作用。因此，公式(I)和公式(I-1)的化合物在预防和/或治疗代谢性疾病（如糖尿病）、脑血管疾病（如中风）等方面有用。
• Piperidine-containing compounds and use thereof
  申请人：Rodriguez Martha E.

  公开号：US08809538B2

  公开（公告）日：2014-08-19

  A method for preventing and/or treating a metabolic disease, cerebrovascular disease, etc. which comprises administering to a mammal an effective amount of the compound of the formula (I): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. And a novel compound of the formula (I-1): wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in a method for preventing and/or treating for a metabolic disease such as diabetes, cerebrovascular disease such as stroke, etc.

  本发明提供了一种预防和/或治疗代谢性疾病、脑血管疾病等的方法，包括向哺乳动物施用化合物(I)的有效量：其中所有符号的含义均如规范中所定义；其盐、N-氧化物、溶剂化物或前药。化合物(I-1)的新型化合物：其中所有符号的含义均如规范中所定义；其盐、N-氧化物、溶剂化物或前药具有抗糖尿病和神经保护作用。因此，化合物(I)和化合物(I-1)在预防和/或治疗代谢性疾病如糖尿病、脑血管疾病如中风等方面是有用的。